Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HROW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$37.64$36.02$28.54▼$54.85$1.40B0.28749,821 shs740,769 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow0.00%+13.41%+20.60%+7.82%+24.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$37.64$36.02$28.54▼$54.85$1.40B0.28749,821 shs740,769 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow0.00%+13.41%+20.60%+7.82%+24.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHROWHarrow 2.64Moderate Buy$69.4384.45% UpsideCurrent Analyst Ratings BreakdownLatest HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.004/22/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/17/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.004/7/2026HROWHarrow B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$74.00 ➝ $65.004/3/2026HROWHarrow Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/19/2026HROWHarrow HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.003/18/2026HROWHarrow NomuraSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral3/18/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHROWHarrow$272.30M5.15$0.86 per share43.55$1.41 per share26.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHROWHarrow-$5.14M-$0.41N/A17.43N/A-5.57%19.59%2.26%8/10/2026 (Estimated)Latest HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHROWHarrowN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHROWHarrow10.302.482.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHROWHarrow72.76%Insider OwnershipCompanyInsider OwnershipHROWHarrow12.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHROWHarrow18037.28 million32.50 millionOptionableHROW HeadlinesRecent News About These CompaniesIs Harrow, Inc. (HROW) A Good Stock To Buy Now?June 13 at 6:10 PM | insidermonkey.comIs Harrow, Inc. (HROW) A Good Stock To Buy Now?June 13 at 5:10 PM | finance.yahoo.comCan Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?June 12 at 8:14 PM | finance.yahoo.comHarrow re-launches Verkazia to improve access for VKC treatmentJune 11, 2026 | thepharmaletter.comTHROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the USJune 11, 2026 | zacks.comHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareJune 10, 2026 | globenewswire.comWhat Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?June 5, 2026 | finance.yahoo.comHarrow Health Releases June 2026 Investor Presentation UpdateJune 3, 2026 | tipranks.comHarrow to Present at William Blair’s 46th Annual Growth Stock ConferenceMay 28, 2026 | finance.yahoo.comHarrow to Present at William Blair's 46th Annual Growth Stock ConferenceMay 27, 2026 | globenewswire.comHarrow, Inc. $HROW Stock Position Raised by Penn Capital Management Company LLCMay 27, 2026 | marketbeat.com12th Street Asset Management Company LLC Makes New $4.47 Million Investment in Harrow, Inc. $HROWMay 26, 2026 | marketbeat.comWhy B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term OptimismMay 22, 2026 | finance.yahoo.comWhy B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term OptimismMay 20, 2026 | insidermonkey.comHarrow: Demand Keeps It Interesting, Valuation Keeps It A HoldMay 20, 2026 | seekingalpha.comInsider Buying: Harrow (NASDAQ:HROW) Director Purchases 1,000 Shares of StockMay 20, 2026 | insidertrades.comHarrow, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 19, 2026 | seekingalpha.comInsider Buying: Harrow (NASDAQ:HROW) CFO Buys 3,500 Shares of StockMay 16, 2026 | insidertrades.comWhy Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay PositiveMay 15, 2026 | finance.yahoo.comCantor Fitzgerald Sticks to Their Buy Rating for Harrow Health (HROW)May 15, 2026 | theglobeandmail.comHarrow stock seeks recovery after plummetMay 13, 2026 | nashvillepost.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHROW Company DescriptionsHarrow NASDAQ:HROW$37.64 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$37.60 -0.05 (-0.12%) As of 06/12/2026 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
